441 related articles for article (PubMed ID: 35955774)
1. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
2. Cannabis constituent synergy in a mouse neuropathic pain model.
Casey SL; Atwal N; Vaughan CW
Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
[TBL] [Abstract][Full Text] [Related]
3. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
4. THC and gabapentin interactions in a mouse neuropathic pain model.
Atwal N; Casey SL; Mitchell VA; Vaughan CW
Neuropharmacology; 2019 Jan; 144():115-121. PubMed ID: 30312630
[TBL] [Abstract][Full Text] [Related]
5. Single and combined effects of Δ
King KM; Myers AM; Soroka-Monzo AJ; Tuma RF; Tallarida RJ; Walker EA; Ward SJ
Br J Pharmacol; 2017 Sep; 174(17):2832-2841. PubMed ID: 28548225
[TBL] [Abstract][Full Text] [Related]
6. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive effects of minor cannabinoids, terpenes and flavonoids in Cannabis.
Rodriguez CEB; Ouyang L; Kandasamy R
Behav Pharmacol; 2022 Apr; 33(2&3):130-157. PubMed ID: 33709984
[TBL] [Abstract][Full Text] [Related]
8. A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.
Nutt DJ; Phillips LD; Barnes MP; Brander B; Curran HV; Fayaz A; Finn DP; Horsted T; Moltke J; Sakal C; Sharon H; O'Sullivan SE; Williams T; Zorn G; Schlag AK
Cannabis Cannabinoid Res; 2022 Aug; 7(4):482-500. PubMed ID: 33998895
[No Abstract] [Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
12. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
13. Distinct antinociceptive and conditioned behavioral effects are produced by individual cannabinoids and a cannabis-derived mixture.
Morris T; Cucinello-Ragland JA; Marks TJ; Prevost K; Glenn JF; Davenport GJ; Edwards S; Winsauer PJ
Pharmacol Biochem Behav; 2024 Feb; 235():173692. PubMed ID: 38128766
[TBL] [Abstract][Full Text] [Related]
14. Effect of cannabidiolic acid and ∆
Rock EM; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2018 Nov; 235(11):3259-3271. PubMed ID: 30225659
[TBL] [Abstract][Full Text] [Related]
15. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
18. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
19. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
20. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Hammond D; Goodman S
Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
